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Background: Duchenne muscular dystrophy (DMD) is due to mutations in the gene coding for human DMD; DMD
is characterized by progressive muscle degeneration, inflammation, fat accumulation, and fibrosis. The mdx mouse
model of DMD lacks dystrophin protein and undergoes a predictable disease course. While this model has been a
valuable resource for pre-clinical studies aiming to test therapeutic compounds, its utility is compromised by a lack
of reliable biochemical tools to quantifiably assay muscle disease. Additionally, there are few non-invasive assays
available to researchers for measuring early indicators of disease progression in mdx mice.
Methods: Mdx mice were crossed to knock-in mice expressing luciferase from the Cox2 promoter. These reporter
mice (Cox2FLuc/+DMD−/−) were created to serve as a tool for researchers to evaluate muscle inflammation. Luciferase
expression was assayed by immunohistochemistry to insure that it correlated with muscle lesions. The luciferase
signal was quantified by optical imaging and luciferase assays to verify that the signal correlated with muscle
damage. As proof of principle, Cox2FLuc/+DMD−/− mice were also treated with prednisolone to validate that a reduction
in luciferase signal correlated with prednisone treatment.
Results: In this investigation, a novel reporter mouse (Cox2FLuc/+DMD−/− mice) was created and validated for
non-invasive quantification of muscle inflammation in vivo. In this dystrophic mouse, luciferase is expressed from
cyclooxygenase 2 (Cox2) expressing cells and bioluminescence is detected by optical imaging. Bioluminescence
is significantly enhanced in damaged muscle of exercised Cox2FLuc/+DMD−/− mice compared to non-exercised
Cox2FLuc/+DMD+/+ mice. Moreover, the Cox2 bioluminescent signal is reduced in Cox2FLuc/+DMD−/− mice in response to a
course of steroid treatment. Reduction in bioluminescence is detectable prior to measurable therapy-elicited
improvements in muscle strength, as assessed by traditional means. Biochemical assay of luciferase provides a
second means to quantify muscle inflammation.
Conclusions: The Cox2FLuc/+DMD−/− mouse is a novel tool to evaluate the therapeutic benefits of drugs intended
to target inflammatory aspects of dystrophic pathology. This mouse model will be a useful adjunct to traditional
outcome measures in assessing potential therapeutic compounds.
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Duchenne muscular dystrophy (DMD) is a disease char-
acterized by muscle degeneration followed by inflamma-
tion, fatty infiltration, and fibrosis. In humans, the
disease results from mutations in the DMD gene coding
for dystrophin, a large cytoskeletal protein that links the
actin cytoskeleton to the subsarcolemmal membrane via
a complex called the dystrophin glycoprotein complex
(DGC) [1-3]. In the absence of dystrophin, the entire
DGC is lost from the membrane and recurrent cycles of
muscle damage, inflammation, and repair ensue. While
muscle regeneration partially compensates for necrosis,
lost muscle is eventually replaced by fibrotic tissue.
The mdx mouse (C57BL/10ScSn-Dmdmdx/J), the gen-
etic homologue for human DMD, is a commonly used
animal model [4-8]. While mdx mice display a less se-
vere phenotype compared to their human counterparts,
pathology and muscle weaknesses are evident morpho-
logically from 3 weeks of age. Subsequently, the muscles
undergo a predictable course of disease. Mdx mice are
weaker than age-matched wild-type mice when evalu-
ated by a variety of muscle strength tests [9]. In addition,
their serum creatine kinase remains elevated throughout
their lives [10]. Thus, the mdx mouse has been a highly
useful tool for pre-clinical studies to facilitate drug dis-
covery for dystrophinopathies.
While the mdx mouse is useful for identification of
pathogenic mechanisms, quantitative assessment of early
disease features (for example, inflammation) is more dif-
ficult to evaluate in this model. This difficulty is due in
part to the unpredictable location of muscle lesions,
which can be asymmetric and focal [10]. Furthermore,
since the sampling of a given muscle section is not al-
ways representative of the entire muscle, assessment of
individual muscle sections may be inaccurate in evaluating
the extent of muscle damage. Thus, models that enable
high throughput, rapid, non-invasive, and longitudinal
assessment of the efficacy of therapeutic compounds in
mice would be a useful resource to muscular dystrophy
researchers.
To address some of these concerns, we generated a
knock-in mouse in which luciferase is expressed from
the Cox2 gene (PTGS2) promoter (Cox2FLuc/+ mice)
[11]. Cox2 is one of the enzymes participating in pros-
taglandin synthesis; it is induced in numerous cell
types, particularly macrophages, which are the predom-
inant immune cell type in dystrophic muscle lesions
[12]. Furthermore, the appearance of macrophages in
dystrophic muscle closely parallels active disease [13],
suggesting that Cox2FLuc/+ mice may be a useful re-
porter to monitor disease progression in mdx mice
(DMD−/−). After crossing the Cox2FLuc/+ mouse to the
DMD−/− mdx background to create Cox2FLuc/+ DMD−/−
mice, we show that dystrophic features of inflammationcan be monitored non-invasively by bioluminescent op-
tical imaging.
A major advantage to using non-invasive, whole-
animal imaging systems for detection of muscle damage
is the ability to obtain quantifiable assessments of the ef-
ficacy of therapeutic candidates. Currently, the primary
method used by researchers to assess muscle damage in
the dystrophies is histopathology. However, this ap-
proach is time consuming and is limited to analysis of
only one or two sections of each muscle. Optical im-
aging systems can detect light from luciferase-expressing
cells after injection of the substrate luciferin. In the pres-
ence of sufficient ATP, Mg, and luciferin, light is pro-
duced in amounts proportional to the amount of
luciferase enzyme expressed. In appropriate circum-
stances, the light can be detected and quantified from
living animals. The procedure is much less expensive
than other methods of imaging, for example, magnetic
resonance imaging or positron emission tomography.
Furthermore, for luciferase-based reporters, the reporter
gene signal is produced only at sites where the enzyme
is expressed, unlike PET imaging where the unbound
radioactive substrates/ligands must be cleared for the re-
porter gene-mediated signal-to-background contrast to
be observed. Where applicable and appropriate, optical
reporter gene imaging provides advantage of ease of use
and low cost in carrying out longitudinal studies [14,15].
In this manuscript, we describe a novel reporter
mouse, useful for assessing pharmacological treatments
for DMD. The Cox2FLuc/+DMD−/− mouse model shows
sufficient sensitivity to both optically and biochemically
quantify changes in damage mediated by steroid treat-
ment. Thus, this mouse model is now an additional tool




Cox2FLuc/+DMD−/− mice were created by crossing the
commonly used model of human DMD, the mdx mouse,
(C57BL/10ScSn-mdx/J) with the cyclooxygenase2 (Cox2)-
luciferase knock-in mouse (Cox2FLuc/+BL/6) created by
our laboratory [11]. The Cox2-luciferase knock-in trans-
gene was always maintained in the heterozygous state.
The Cox2 knock-in mouse was crossed to the C57BL/6
background five times and then crossed to mdx (C57BL/
10ScSn-Dmdmdx/J, Jackson labs) to create Cox2FLuc/+
DMD−/− mice. Mice expressing the Cox2FLuc allele on the
wild-type DMD+/+ background (identified as Cox2FLuc/+
DMD+/+) were used as controls to assess background sig-
nal. All animal work was conducted under protocols ap-
proved by the UCLA Animal Research Committee in the
Office of Animal Research Oversight (protocol numbers
ARC# 1998–078 and ARC#2009-029).
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Mice used for imaging were given a running wheel at
3 weeks of age (InnoDome and InnoWheel, Bio Serv,
Flemington, NJ). Wheels remained in the cages through-
out the experiment. Running wheels were cleaned, auto-
claved, and replaced weekly. In addition, 2 days prior to
imaging, mice were exercised on an Eco 3/6 treadmill
(Columbus Instruments, Columbus, OH) to exacerbate
the dystrophy. Cox2FLuc/+DMD−/− mice were subjected
to 20 min of running at 19 m/min on a decline of 8°.
Cox2FLuc/+DMD+/+ mice were not exercised so that basal
levels of signal could be determined, independent of
muscle damage.
In vivo bioluminescent imaging
Bioluminescence was assessed using the Xenogen IVIS
Imaging system (STTARR, Toronto, ON, Canada). One
day prior to imaging, mouse legs were shaved. Mouse
cages were warmed for 20 min on heating plates at 37°C,
and temperature support was maintained during luciferin
uptake and imaging. Mice were anesthetized and main-
tained on 1.5% to 2% isoflurane gas anesthesia in oxygen.
After mice were weighed, they were injected intraperito-
neally with D-luciferin (125 mg/kg) and immediately
placed supine in a sealed imaging chamber. Images were
acquired using medium binning and one-minute expo-
sures at 15, 20, 25, and 30-minute time points after D-
luciferin injection. Using the Living Image®4.0 software
(Perkin Elmer, Waltham, MA), regions of interest were
created around the hindlegs. Bioluminescence was quan-
tified with Living Image software to determine max radi-
ance (photons).
Cardiotoxin-induced injury
To assess the ability of optical imaging to detect muscle
damage, we induced acute muscle damage by cardio-
toxin (CTX) injection (50 μl of 10 μM) to the gastrocne-
mius muscle of Cox2FLuc/+DMD+/+ mice [16]. The
contralateral leg was not injected. Two days later, mice
were assessed by optical imaging, as described above. At
the completion of the imaging session, mice were given
a second injection of luciferin and, after 10 min, the
mice were sacrificed, the muscles were dissected, placed
in a petri dish, and imaged ex vivo.
Wire test
Mice were tested by wire test as previously described
[12]. Briefly, mice were placed on a wire secured 2 ft
above a safety net and allowed to use forelimbs and hin-
dlimbs (but not their tail) to hang. Each mouse was sub-
jected to five trials, with 1 minute of rest between trials.
Hang time was recorded from the moment the experi-
menter placed the mouse onto the wire until the mousefell onto the safety net. The five data points were aver-
aged and normalized by body weight.
Prednisolone steroid treatment
Female and male mice were treated with 0.75 mg/kg of
prednisolone, 21-hemisuccinate sodium salt (Sigma, St
Louis, MO) in sterile phosphate-buffered saline (PBS)
[17]. Treated mice received intraperitoneal injections
5 days a week, beginning from 2 weeks of age until mus-
cles were harvested. Prior to each injection, mice were
weighed and the dosage was adjusted. Control mice re-
ceived equal volumes of PBS via intraperitoneal injections.
Immunohistochemistry
Immunohistochemistry was carried out on 10 μm frozen
sections, as previously described [13]. Muscles to be
assayed by immunohistochemistry were harvested and
placed in OCT (Sakura Finetek, Torrance, CA, USA)
then frozen in isopentane cooled by liquid nitrogen.
Muscles were cross-sectioned (10 μm) and stained using
the MOM kit (Vector Laboratories, Burlingame, CA,
USA) and either the AEC Peroxidase Substrate Kit
(Vector Laboratories) or using fluorophore-conjugated
antibodies. Antibodies used were developmental myosin
heavy chain (1:25, Leica Biosystems, Teban Gardens
Crescent, Singapore), CD11b (1:50, BD PharMingen,
San Diego, CA, USA), CD68 (1:50, BD PharMingen),
and luciferase (1:25, Promega, Madison, WI, USA). Im-
ages were acquired using a compound microscope
(Zeiss, Ontario, CA, USA), processed using AxioVision
software (Zeiss), and displayed using Photoshop CS4
(Adobe, Mountain View, CA, USA).
Luciferase assay
Luciferase assay of muscles ex vivo was performed using
the Promega Luciferase Assay Kit (cat# E1500, Promega)
according to the manufacturer’s recommendations with
minor modification. In brief, 40 to 100 mg of frozen
muscle was powdered with mortar and pestle in liquid
nitrogen. Powder was transferred to 1.5 ml tubes, and
0.5 ml of Passive Lysis Buffer (PLB; Cat# E1941, Pro-
mega) was added to the tube. Extraction was performed
for 1 h at 4°C with rotation followed by 3 cycles of freez-
ing/thawing in liquid nitrogen or 30°C water bath. Sam-
ples were vortexed after each thawing cycle for 1 min at
room temperature. Samples were then subjected to centri-
fugation at 10,000 g for 15 min at 4°C. Clarified superna-
tants were transferred to new tubes and stored at −80°C
until used for luciferase assay and protein concentration
measurements. For luciferase assay, 20 μl of sample were
mixed with 100 μl of assay reagent and luciferase activity
was recorded immediately using a Promega GloMax
2020 Luminometer. The amount of luciferase in the
sample was calculated using the standard curve prepared
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ciferase (cat# E1707, Promega). The amount of protein in
the sample was measured using the 660 nm Protein assay
kit (Pierce, cat#22660, Life Technologies, Grand Island,
NY, USA) with bovine serum albumin (BSA) used as a
standard. All measurements were performed in triplicate.
Tissue extract preparation and western blot analysis
For western blot analysis, gastrocnemius muscles from
Cox2FLuc/+ mice were homogenized in reducing sample
buffer (80 mM Tris, pH 6.8, 0.1 M dithiothreitol, 2%
SDS, and 10% glycerol with protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO, USA)) using a Dounce
homogenizer. Protein extracts were boiled for 1 minute,
placed on ice, and loaded to SDS PAGE (40 μg per well)
followed by transfer to nitrocellulose membrane (100 V,
1 h, 4°C). As a positive control, 7.5 ng of QuantiLum re-
combinant luciferase (Promega, E1701) was used. Mem-
branes were stained with Ponceau red and imaged and
then blocked with 3% BSA and probed with anti-luciferase
antibody (Promega, 1:1,000) followed by anti-rabbit IgG
peroxidase conjugate (Sigma-Aldrich). Blots were devel-
oped using ChemiGlow West substrate (ProteinSimple,
San Jose, CA, USA) and detected using an AlphaImager
gel documentation system (formerly Alpha Innotech, now
ProteinSimple). The actin band from the Ponceau stained
membrane served as the loading control.
Statistical analysis
For optical imaging, the four images that were acquired
at 15, 20, 25, and 30 min were averaged. At each of these
four time points, both legs of each animal were averaged
and this number was used as the data point. Thus, each
point for data analysis included both the average of the
four imaging time points over 15 min and the average of
both the left and right legs. Data were analyzed by re-
peated measure analysis of variance (ANOVA). For
ANOVA, data were converted to log (base e) scale for
the average of max radiance for each treatment group.
For wire strength tests and biochemical luciferase assays,
data were analyzed by t-test, with P < 0.05 considered
statistically significant.
Results
Bioluminescence is detectable in muscles from
cardiotoxin-injured Cox2FLuc/+ mice
Muscle injury studies were carried out to determine
whether the luciferase signal generated by the Cox2 pro-
moter in Cox2FLuc/+ mice was sufficiently strong to be
detectable by optical imaging. To induce injury, cardio-
toxin was injected to the area of the leg containing the
gastrocnemius and hamstring muscles in three mice.
One hind leg of each Cox2FLuc/+ mouse (on a mixed
C57B6/B10 wild-type background) was injected withcardiotoxin. The opposing muscle of each mouse was
not injected and served as a control. Forty-eight hours
after injection the mice were anesthetized, injected with
luciferin, and subjected to optical imaging. The injected
leg showed a bioluminescent signal, while the uninjected
leg did not give a bioluminescent signal. Representative
data from one mouse are shown in Figure 1A. Since
male mice had a non-specific signal, presumably from
the genitalia, we determined that only female mice could
be used for these experiments. After imaging was com-
pleted, the mice were injected again with D-luciferin.
Ten minutes later, the muscles from the left and right
hind legs were harvested and imaged ex vivo in a petri
dish (Figure 1B). Because it was difficult to precisely in-
ject specific muscles with the cardiotoxin, both gastro-
cnemius and hamstring muscles of the leg were
dissected for imaging. For two of the animals, only one
of the two pieces of dissected, cardiotoxin-injected ham-
string muscle produced a bioluminescent signal, while
none of the muscle sections from the uninjected legs,
imaged under the same circumstances, showed a signal.
It is likely that cardiotoxin did not penetrate all sections
of the muscles in the injected leg; the likely explanation
for why only two of the three sections showed a signal.
Muscles from the three mice were also assessed for lu-
ciferase expression by western blotting, confirming the
increase in luciferase protein following injury (Figure 1C).
Thus, these data suggest that detection of muscle dam-
age in vivo by optical imaging is achievable using
Cox2FLuc/+ mice.
Generation of Cox2FLuc/+DMD−/− mice for optical imaging
of dystrophic lesions
The above studies validated that the Cox2FLuc reporter
can generate a detectable optical signal following muscle
damage. We next sought to use this reporter to cre-
ate a dystrophic model to detect muscle inflammation
and damage by non-invasive optical imaging. To gen-
erate the model, the Cox2FLuc/+ mouse was crossed to
the mdx (DMD−/−) mouse (hereafter referred to as
Cox2FLuc/+DMD−/− mice) and the Cox2FLuc transgene was
maintained in the heterozygous state. To assess back-
ground signal, Cox2FLuc/+ mice on the WT DMD+/+
background (Cox2FLuc/+DMD+/+ mice) were imaged in
parallel.
Optical imaging of the Cox2FLuc reporter detects damage
in dystrophic muscle
To evaluate whether the Cox2-luciferase signal arising
from dystrophic lesions can be detected by optical imaging,
we imaged Cox2FLuc/+DMD−/− mice and age-matched
Cox2FLuc/+DMD+/+ mice from ages of 5 to 9 weeks. To ex-
acerbate muscle damage, Cox2FLuc/+DMD−/− mice were
provided running wheels at all times and were also
Figure 1 Damaged Cox2FLuc/+DMD+/+ muscle exhibits a bioluminescent signal that is detectable by optical imaging. Optical imaging was carried out
on mice injured by cardiotoxin to determine whether the bioluminescent signal induced by muscle damage was detectable. Acute injury was induced
by cardiotoxin injection into the lower leg muscles of Cox2FLuc/+DMD+/+ mice while the opposing leg muscles were not injected. Mice were imaged
48 h post cardiotoxin injection. (A) In vivo bioluminescent signal is shown in pseudo color for one representative mouse. Bioluminescence was
observed from the cardiotoxin-injured leg but not from the uninjected leg. Red box in the left panel is shown in higher magnification on the right side
of the figure. (B) After the first imaging session, the mice were injected again with D-luciferin and the gastrocnemius and hamstring muscles from the
left and right legs were dissected, placed in a petri dish, and re-imaged ex vivo. Bioluminescence is shown, in pseudo color, for two of the three mice.
Only muscle sections from the cardiotoxin-injected legs produced a bioluminescent signal detected by optical imaging. (C) Western blot of luciferase
detected in whole muscle extracts from uninjected (C) and injected (I) muscles. (Luc) is the luciferase control (recombinant protein) run on the same
gel. The actin band from the ponceau red stained nitrocellulose membrane was used as a loading control.
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aging. Cox2FLuc/+DMD+/+ mice were not exercised, so the
background signal emanating from the transgene could be
determined. The luciferase signal was best visualized on
the quadriceps and hamstring muscles when mice were
lying with the ventral surface facing up (Figure 2A). For
each mouse, a region of interest on the hindlimb was cir-
cled and bioluminescence measured. The signal was stable
from 15 to 30 min following luciferin injection (Figure 2B).
Mice were imaged once weekly, over a period of 5 weeks
(5 to 9 weeks of age) (Figure 2C). A significant difference
could be observed between Cox2FLuc/+DMD−/− (damaged
muscle) and Cox2FLuc/+DMD+/+ (healthy muscle) from 6to 9 weeks of age, by analysis of variance analyses.
Cox2FLuc/+DMD−/− exercised mice showed approximately
40% higher Max Radiance at the time points between 6
and 8 weeks of age, compared to age-matched, non-
exercised Cox2FLuc/+DMD+/+ mice (Figure 2C).
Luciferase expression ex vivo was assayed in the ham-
string, gastrocnemius, and tibialis anterior muscles
using a luciferase assay kit. As observed in vivo, mus-
cles from Cox2FLuc/+DMD−/− mice showed significantly
higher luciferase expression compared to those from
Cox2FLuc/+DMD+/+ mice (Figure 2D). We observed a much
larger differential signal between DMD+/+ and DMD−/−
genotypes when luciferase was assayed biochemically
Figure 2 Optical imaging detects muscle damage in exercised Cox2FLuc1/+DMD−/− mice. (A) Representative bioluminescent image taken 25 min after
D-luciferin injection into 6-week-old female exercised Cox2FLuc/+DMD−/− mice and non-exercised Cox2FLuc/+DMD+/+ mice. (B) Representative example of
data obtained from a group of mice imaged at 6 weeks of age, demonstrating the stability of the bioluminescent signal over the imaging period.
(Cox2FLuc/+DMD+/+ N = 14, Cox2FLuc/+DMD−/− N = 17) (C) The optical imaging data are graphed as log base e (Cox2FLuc/+DMD+/+ N = 15, 14, 14,
15, 24, and Cox2FLuc/+DMD−/− N = 18, 17, 19, 20, 35) at 5, 6, 7, 8, and 9 weeks of age. (D) Ex vivo luciferase enzymatic assays of gastrocnemius,
hamstring, and tibialis anterior muscles harvested from Cox2FLuc/+DMD−/− (N = 6) mice and Cox2FLuc/+DMD+/+ (N = 3) mice. Mice were 6 to
9 weeks of age. (E) Representative cross sections of 8 week old Cox2FLuc /+DMD+/+(left) and Cox2FLuc/+DMD−/− (right) muscles, stained with a
macrophage marker CD68 (red) and counterstained with hematoxylin (blue). (F) Muscle strength testing in Cox2FLuc /+DMD−/− mice (N = 9, 15,
11, 11, and 11) and Cox2FLuc/+DMD+/+ mice (N = 7, 6, 6, 6, and 5) at 5, 6, 7, 8, and 9 weeks of age.
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son for this difference relates to the limited resolution
of optical imaging of whole muscle. While the reso-
lution of optical imaging is a limitation of this tech-
nique, the ability to obtain insight into the status of
muscle inflammation in a non-invasive, repetitive, and
localized manner counterbalances this limitation to
some extent. The ability to assay luciferase at the con-
clusion of the experiment provides an additionalmeasurement to quantify muscle inflammation and
adds to the utility of this mouse model. Comparison of
the optical imaging and luciferase data for the last
measurement for each mouse provides some degree of
comparison for the in vivo and ex vivo evaluations of
Cox2 promoter-driven gene expression.
Functional and histological studies were also carried
out on Cox2FLuc/+DMD−/− mice to ensure that the mice
maintained a dystrophic phenotype. To verify that
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ically seen in DMD−/− muscles, cross sections of
Cox2FLuc/+DMD−/− muscles were stained for macrophages,
and visual inspection confirmed the presence of muscle
damage (Figure 2E). To evaluate muscle strength, conven-
tional wire test assays were conducted. Cox2FLuc/+DMD−/−
mice and Cox2FLuc/+DMD+/+ mice were strength-tested
once weekly from 5 to 9 weeks of age. Forty-eight hours
prior to performing the functional tests, Cox2FLuc/+
DMD−/− mice were exercised on a treadmill for 20 min to
exacerbate muscle damage. Similar to mdx mice [12],
Cox2FLuc/+DMD−/− mice showed muscle weakness by wire
test compared to age-matched Cox2FLuc/+DMD+/+ mice
(Figure 2F).
Identification of cell types expressing the Cox2FLuc
reporter in muscle cross sections
Muscle cross sections from Cox2FLuc/+DMD−/− mice
were stained with a luciferase antibody to validate the
specificity of the luciferase signal and to identify the cellu-
lar source of luciferase expression. The luciferase antibody
signal co-localized with areas that were morphologically
distinguishable as dystrophic lesions, corroborating theFigure 3 Luciferase signal colocalizes to CD68+ and CD11b + immune ce
Cox2FLuc/+DMD−/− mouse quadriceps, fluorescently labeled with antibodie
myosin heavy chain (dMHC) (red) (C), and CD11b (red) (D). (A), (B), and (C) ar
three sections. The yellow arrowheads in A and C show a regenerating fiber t
points to a patch of regenerating fibers that are luciferase negative. The area
regenerating fibers that are both dMHC negative and luciferase negative. The
(green) and CD11b (red, a marker for immune cells). Double stained areas of
DAPI (blue) and were photographed at 20× magnification.conclusion that Cox2 promoter-driven luciferase is a valid
indicator of muscle pathology (Figure 3). A robust lucifer-
ase signal (shown in green (Figure 3A, D)) co-localized
with markers of immune cells; both the M1 macrophage
marker CD68 (red color, Figure 3B) or the pan-immune
marker CD11b (red color, Figure 3D) co-localized with
the luciferase signal (yellow color).
Since small regenerating developmental myosin heavy
chain (dMHC+) muscle fibers co-localize to dystrophic
lesions, we sought to determine whether these newly de-
veloping fibers might also express luciferase. To assess
the luciferase signal from regenerating fibers, we com-
pared serial sections stained by either luciferase or
dMHC. Comparison of fibers that stained positively for
dMHC (Figure 3C) did not reveal a correspondingly
strong luciferase signal (Figure 3A) in the same dMHC+
cells (compare red stained structure denoted by yellow
arrowhead in Figure 3C to yellow arrowhead in corre-
sponding section of 3A. Similarly, compare structures
denoted by white arrows in Figure 3A compared to 3C).
Fibers that were regenerating, but no longer expressing
dMHC, were clearly negative for luciferase expression
(see the area circled by a dotted line in panels A and Clls in Cox2FLuc/+DMD−/− muscle cross sections. Cross sections of
s to luciferase ((A) and (D), in green), CD68 (red) (B), developmental
e serial sections in which asterisks indicate the same fibers in each of the
hat is dMHC positive but luciferase negative. Similarly, the white arrow
outlined by the dotted lines in panels (A) and (C) shows a cluster of late
micrograph in (D) shows a muscle lesion double-labeled with luciferase
panel (D) appear as yellow. All cross sections were counterstained with
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emanating from muscles of Cox2FLuc/+DMD−/− mice lo-
calizes to dystrophic lesions and derives from immune
cells.
Therapeutic benefit of anti-inflammatory steroids is
quantifiable by optical imaging
Treatment with anti-inflammatory steroids is standard
of care for patients with DMD, due to the ability of these
drugs to extend ambulation in boys with DMD by 3 to
5 years. Mdx mice treated with the steroid prednisolone
demonstrate initial strength benefits but develop more
advanced cardiac fibrosis than non-treated mdx mice
after 100 days [17]. While steroid treatment of mice does
not replicate all the physiological benefits of steroid
treatment in humans, the short-term benefit provides a
good model to assess the sensitivity of optical imaging to
early changes in muscle inflammation.
To address the question of whether optical imaging
could detect modulation of muscle inflammation after
steroid treatment, Cox2FLuc/+DMD−/− mice were treated
with 0.75 mg/kg of prednisolone 5 days a week (starting
at 2 weeks of age); control Cox2FLuc/+DMD−/− mice were
injected with an equal volume of PBS. Mice were imaged
weekly from 5 to 12 weeks of age. Two days prior to im-
aging, all mice were exercised for 20 min downhill on a
treadmill. Prednisolone significantly reduced the lucifer-
ase signal in 5 to 8-week-old mice, when compared to
PBS-treated Cox2FLuc/+DMD−/− mice (Figure 4A, B, C,
D). ANOVA revealed a reduction in bioluminescent sig-
nal when mice were imaged at 5, 6, 7, and 8 weeks of
age following prednisolone treatment. While there was a
trend towards a reduced signal in the prednisolone vs
PBS-treated muscles at all of the time points between 5
to 8 weeks of age, post hoc analysis revealed statistical
significance at the 6-week time point and after all mice
from the 5- to 8-week time points were analyzed to-
gether. After 8 weeks, differences in signal could not be
demonstrated between the treatment groups.
Ex vivo luciferase activity was assayed in quadriceps
muscles of mice from 7 to 10-week-old treated Cox2FLuc/+
DMD−/− mice, compared to Cox2FLuc/+DMD−/− mice
injected with PBS; prednisolone treatment resulted in
a significant reduction in luciferase activity in quadri-
ceps muscles from mice that were 7 to 10 weeks old
(Figure 4E) (P = 0.002). Similar to the findings presented
in Figure 2, biochemical assessment of luciferase by ex vivo
luciferase enzymatic assay appeared to be a useful indica-
tor of disease activity, even after the difference in treat-
ment groups by luciferase optical imaging was no longer
distinguishable.
Muscle strength assays did not detect a difference in
strength between treated and untreated Cox2FLuc/+DMD−/−
mice until 10 to 12 weeks of age (Figure 4F). Thus, Cox2promoter-driven luciferase optical imaging detected the
earlier, anti-inflammatory effects of prednisolone treatment
in the muscle prior to the ability to measure functional
improvements in muscle strength. These studies dem-
onstrate that the Cox2FLuc/+DMD−/− mouse is useful for
non-invasive detection of early stages of dystrophic dis-
ease and for therapeutic modulation of inflammation at
the early stages of disease (5 to 8 weeks). The mouse
model is also useful for biochemically quantifying Cox2
promoter-driven luciferase as an evaluation of inflam-
mation in whole muscles in mice 7 to 10 weeks of age
Thus, this model provides the opportunity for both
non-invasive and biochemical assessment of inflamma-
tion in dystrophic muscles. These data validate the
Cox2FLuc/+DMD−/− mouse as a useful model to detect
and monitor muscle inflammation, both non-invasively
and biochemically.
Discussion
Translation in muscular dystrophy research has been
hindered by a scarcity of reproducible, quantitative out-
come measures to assess disease severity in mouse
models. While the mdx mouse is a valid model of DMD,
this mouse must be used in an informed manner to ob-
tain accurate and interpretable data that enables identifi-
cation of drugs that have the potential to attenuate the
clinical disease course in humans [5,8,10]. Despite the
utility of the mdx model, there is a need for new models
that are useful for assessing pharmacological interven-
tions, especially models that allow for data to be col-
lected repeatedly from the same mouse, in longitudinal
studies.
In this study we sought to create a mouse model that
would allow researchers to carry out non-invasive, re-
peated, longitudinal assessment of therapeutic inter-
ventions and to provide an efficient alternative to
conventional analyses of disease progression. When
attempting to evaluate improvements in muscle strength
following an intervention, dystrophy researchers often use
a series of functional assays; these assays, while inform-
ative of late aspects of disease progression, are often not
useful for assessment of early events in dystrophic disease.
For example, while prednisolone treatment of mdx mice
consistently improves muscular strength, functional
benefit cannot be measured until 8 weeks post treat-
ment (Figure 4F). In contrast, non-invasive optical im-
aging of luciferase expression from the endogenous
Cox2 promoter in Cox2FLuc/+DMD−/− knock-in mice
can detect changes in the inflammatory milieu as early
as 3 weeks after the start of prednisolone treatment
(Figure 4D). Moreover, additional data on the state of
muscle inflammation can also be obtained at sacrifice
of the mouse by ex vivo monitoring of luciferase activ-
ity, increasing the utility of this mouse model.
Figure 4 Bioluminescent signal is reduced in prednisolone-treated Cox2FLuc/+DMD−/− mice. Mice were treated with 0.75 mg/kg of prednisolone or with
PBS for 5 days a week starting at 2 weeks of age. Imaging was initiated at 5 weeks of age. (A) Representative bioluminescent images taken 25 min after
D-luciferin injection into prednisolone-treated Cox2FLuc/+DMD−/− mice at 6 weeks of age (two mice, far right), PBS-treated Cox2FLuc/+DMD−/− mice
(two mice, far left), a control Cox2FLuc/+DMD+/+ mouse (one mouse, middle), and (B) representative images from mice imaged at 8 weeks of age (PBS
treated on left, prednisolone treated on right). All mice were females. (C) Representative example of one imaging time point (6 weeks of age) showing
the stability of the signal over the 30 min imaging period. (Prednisolone, N = 37; PBS N = 39). (D) Optical imaging data from prednisolone (N = 35, 37,
38, 34) and PBS (N = 33, 39, 37, 37) treated Cox2FLuc/+DMD−/− mice from 5 to 8 weeks of age. Bars represent standard errors. Data are expressed as max
radiance and graphed as log base e, (E) luciferase assays of quadriceps muscles harvested from 7 to 10-week-old prednisolone and PBS-
treated Cox2FLuc/+DMD−/− mice. (F) Wire strength test of prednisolone-treated (N = 29, 24, 21, 16, 17, 16, 12 15, 11, 9, 13, 7, and 7) and age-
matched control (N = 25, 29, 22, 17, 17, 13, 16, 16, 14, 13, 16, 5, and 9) Cox2FLuc/+DMD−/− mice for ages 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
and 17 weeks. *P < 0.05; PBS, phosphate-buffered saline.
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histology, may be useful to evaluate drug efficacy, this
procedure is labor intensive, subjective, and compromised
by sampling bias due to the patchy and asymmetric natureof dystrophic lesions [10]. Optical imaging provides an al-
ternative/supplemental assay to quantitative histology,
since multiple muscles are simultaneously sampled and
the optical signal is quantified. Moreover, use of tissue
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time point for every analysis, increasing both the uncer-
tainty resulting from inter-animal variability in disease
progression as well as differences in pharmacokinetics and
pharmacodynamics in individual animals. In contrast,
using non-invasive, repeated, longitudinal analysis by bio-
luminescence imaging in the Cox2FLuc/+DMD−/− mouse
essentially makes each animal its own control. While there
is clear and important value in carrying out histological
assessments, there is added value in the ability to initially
image non-invasively and to then examine the muscle sec-
tions in the same animal. Further analysis of luciferase by
biochemical assay after the animal is sacrificed provides
additional information. Thus, the Cox2FLuc/+DMD−/−
mouse model provides both the ability to non-invasively
image aspects of disease progression, followed by trad-
itional histological and luciferase assays.
Two other mdx models are available for non-invasive
optical imaging. One relies on injection of caged cathep-
sin compounds into mdx mice [18]. This model offers
many of the benefits of the model described here. A sec-
ond model, using the Pax7 promoter to drive luciferase
expression, is useful for non-invasively quantifying re-
generation [19]. The muscles of this ‘regeneration re-
porter’ mouse accumulate luciferase signal over the life
of the SJL mouse (dysferlin-deficient) by perpetually add-
ing nuclei from satellite cells to differentiated muscle.
This latter model, when crossed to the mdx mouse,
would be useful to test potential therapeutic compounds
in tandem with the Cox2FLuc/+DMD−/− mouse to obtain
a better evaluation of both early and long-term benefit.
While the Cox2FLuc/+DMD−/− mouse offers an alterna-
tive to other methodologies, there are some limitations
to this model. The primary utility of the model is the
ability to non-invasively detect inflammation in mice less
than 9 weeks of age, when the extent of necrosis is most
severe; consequently, its primary value is in assessment
of early inflammatory events. Because of the non-
invasive aspect of the analysis, multiple time points can
be assessed to obtain more extensive data (see Figure 2).
If long-term studies are required, luciferase can be quan-
tified biochemically by ex vivo enzymatic analysis at the
expense of requiring sacrifice of each mouse. We suggest
that the Cox2FLuc/+DMD−/− mouse will be most useful to
evaluate therapeutic interventions that impact the im-
mune system. This model will also be valuable to assess
interventions that stabilize the muscle membrane, since
inflammation is expected to be attenuated following
treatments that strengthen the plasma membrane (for
example, AAV micro-dystrophin, membrane sealant
poloxamer, utrophin upregulation) [20-22]. We suggest
that the Cox2FLuc/+DMD−/− mouse model, which pro-
vides both a non-invasive method to assess muscle in-
flammation in early stages of disease progression and abiochemical alternative to characterize inflammation in
later disease stages, will best be used as one of many
outcome measures of disease.
Conclusions
This study describes and validates an inflammation-
reporter mouse that is useful for non-invasively and
repeatedly assessing therapeutic interventions that re-
duce muscle inflammation. This model should ultimately
be used in conjunction with functional tests, bioche-
mical assessments, and alternative non-invasive imaging
models to evaluate the benefit of potential therapeutic
interventions.
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